Equity · Healthcare
ENTA
NASDAQEnanta Pharmaceuticals (ENTA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 400.2M USD
- Revenue, year to Sep 2025
- 65.3M USD
- EPS, diluted, year to Sep 2025
- −3.84 USD
- 52-week range
- 6.50 USD – 16.85 USD
- Avg volume
- 43.8K
as of Jul 17, 2026
Have Enanta Pharmaceuticals (ENTA) insiders bought or sold shares recently?
ENTA's newest Form 4 filing is dated 8 August 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 05 Dec 2025 | Luly Jay R.President and CEO | Sell | 4,743 | 67K USD |
| 05 Dec 2025 | Or Yat SunChief Scientific Officer | Sell | 2,390 | 34K USD |
| 05 Dec 2025 | Kieffer Tara LynnChief Product Strategy Officer | Sell | 2,106 | 30K USD |
| 05 Dec 2025 | Luu BrendanChief Business Officer | Sell | 1,394 | 20K USD |
| 05 Dec 2025 | Rottinghaus Scott T.Chief Medical Officer | Sell | 798 | 11K USD |
| 05 Dec 2025 | Trout Harry R. IIISee Remarks | Sell | 542 | 8K USD |
| 05 Dec 2025 | Capps Kathleen S.See Remarks | Sell | 323 | 5K USD |
| 02 Dec 2025 | Trout Harry R. IIISee Remarks | Sell | 380 | 5K USD |
| 02 Dec 2025 | Capps Kathleen S.See Remarks | Sell | 207 | 3K USD |
| Sold | 9 open-market sales | 12,883 | $183K |
27 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 08 Aug 2026 | Rottinghaus Scott T.Chief Medical Officer | Tax withheld | 1,467 | 20K USD |
| 12 Feb 2026 | Luly Jay R.President and CEO | Award | 20,000 | |
| 12 Feb 2026 | Luly Jay R.President and CEO | Tax withheld | 6,155 | 88K USD |
| 12 Feb 2026 | Or Yat SunChief Scientific Officer | Award | 6,875 | |
| 12 Feb 2026 | Or Yat SunChief Scientific Officer | Tax withheld | 3,413 | 49K USD |
| 12 Feb 2026 | Rottinghaus Scott T.Chief Medical Officer | Award | 6,875 | |
| 12 Feb 2026 | Rottinghaus Scott T.Chief Medical Officer | Tax withheld | 3,413 | 49K USD |
| 12 Feb 2026 | Kieffer Tara LynnChief Product Strategy Officer | Award | 6,562 | |
| 12 Feb 2026 | Kieffer Tara LynnChief Product Strategy Officer | Tax withheld | 3,257 | 46K USD |
| 12 Feb 2026 | Luu BrendanChief Business Officer | Award | 6,562 | |
| 12 Feb 2026 | Luu BrendanChief Business Officer | Tax withheld | 3,257 | 46K USD |
| 12 Feb 2026 | Kowalsky Matthew PaulChief Legal Officer | Award | 5,493 |
Showing the 12 most recent of 27 compensation filings in this window. The figures above count all of them.
Which funds hold Enanta Pharmaceuticals (ENTA)?
8 of the 45 institutional funds we track reported a Enanta Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 25.7M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Trimmed | 643,967 | 9.4M USD | −27.0% |
| Renaissance Technologies | Held (±25%) | 557,600 | 8.1M USD | −16.2% |
| AQR Capital Management | Held (±25%) | 256,870 | 3.7M USD | −18.0% |
| Marshall Wace | Trimmed | 131,995 | 1.9M USD | −37.2% |
| Two Sigma Investments | Trimmed | 71,162 | 1.0M USD | −73.4% |
| Citadel Advisors | Trimmed | 50,844 | 741K USD | −80.6% |
| D. E. Shaw & Co. | Trimmed | 34,539 | 504K USD | −51.3% |
| Balyasny Asset Management | New position | 14,915 | 217K USD | |
| Man Group | Exited | |||
| Tudor Investment Corp | Exited |
Have members of Congress traded Enanta Pharmaceuticals (ENTA)?
The most recent congressional trade disclosed in Enanta Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 12 Jul 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Jul 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 32 days |
What has been filed or recorded for Enanta Pharmaceuticals (ENTA)?
The filings we hold for Enanta Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 02 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 13 USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.67 USD | |
| 30 Jun 2026 | Financials | Total assets | 296.9M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 101.1M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.45 USD | |
| 31 Dec 2025 | Quarterly earnings | Q1 2026 reported | EPS −0.42 USD | |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS −3.84 USD | |
| 30 Sep 2025 | Financials | Revenue | 65.3M USD | fiscal year |
| 30 Sep 2025 | Financials | Net income | −81.9M USD | fiscal year |
| 30 Sep 2025 | Financials | Diluted EPS | −3.84 USD | fiscal year |
| 30 Jun 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.85 USD | |
| 31 Mar 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.06 USD | |
| 31 Dec 2024 | Quarterly earnings | Q1 2024 reported | EPS −1.05 USD | |
| 30 Sep 2024 | Annual report | FY 2024 reported | EPS −5.48 USD |
What do people ask about Enanta Pharmaceuticals (ENTA)?
What is Enanta Pharmaceuticals’ market cap?400.2M
Enanta Pharmaceuticals is worth 400.2M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Enanta Pharmaceuticals’ revenue?65.3M
Enanta Pharmaceuticals reported revenue of 65.3M USD for the year ended 30 Sep 2025, as filed with the SEC. See Filings
Have Enanta Pharmaceuticals insiders bought or sold shares recently?
No Enanta Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 8 Aug 2026 (SEC Form 4). See Insiders
Which funds own Enanta Pharmaceuticals?8 of 45
8 of the 45 funds we track reported a Enanta Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Renaissance Technologies and AQR Capital Management. See Funds
Have members of Congress traded Enanta Pharmaceuticals?1 trade
Yes. 1 trade in Enanta Pharmaceuticals appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 12 Jul 2023, filed 13 Aug 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Enanta Pharmaceuticals last report earnings?−0.67
Enanta Pharmaceuticals last reported earnings on 30 Jun 2026 for Q3 2026, with EPS of −0.67 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings